IOL Chemicals & Pharmaceuticals said that it has commenced the commercial production of 'Paracetamol' with installed capacity of 1,800 MTPA along with backward integration of Para Amino Phenol (PAP) with effect from 22 April 2022.
The Paracetamol, also known as acetaminophen, is an Active Pharma ingredient (API) that is used to treat fever and mild pain, whereas PAP is used as an intermediate to manufacture Paracetamol.
The company is manufacturing Paracetamol in its existing unit number 4, which has been converted as multiproduct facility, with a cost of about Rs 1 crore whereas PAP is being manufactured in part of unit number 9. The company shall continue to use unit 4 & unit 9 for manufacturing other products as per market conditions.
Further, considering the present market scenario, the company is in the process of enhancing the installed capacity for manufacturing the Paracetamol from 1,800 MTPA to 3,600 MTPA with a capex of about Rs 25 crore, which is expected to be completed during the 3 quarter of FY2023. All the capex is being met through internal accruals only, the company said.
IOL Chemicals & Pharmaceuticals is one of the leading pharmaceutical (APIs) company and is significant player in the specialty chemicals space. The company's product portfolio includes APIs such as ibuprofen, metformin, fenofibrate, clopidogrel, lamotrigine, pantoprazole and specialty chemicals such as ethyl acetate, iso butyl benzene, mono chloro acetic acid and acetyl chloride.
The company's net profit declined 65.10% to Rs 40.07 crore on a 8.21% increase in sales to Rs 555.14 crore in Q3 FY22 over Q3 FY21.
The scrip shed 0.22% to end at Rs 455.20 on the BSE yesterday.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU